Los Angeles Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Los Angeles Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22M	Buy	399,542 +381,520	+2,117%	+$1.51M	﹤0.01%	697
2026 Q1	$81.1K	Buy	+18,022	New	+$72K	﹤0.01%	1392
2019 Q2	–	Sell	-888	Closed	-$29K	–	1387
2019 Q1	$29K	Hold	888	–	–	﹤0.01%	1345
2018 Q4	$53K	Sell	888 -15	-2%	-$1.48K	﹤0.01%	1254
2018 Q3	$127K	Buy	903 +5	+0.6%	+$607	﹤0.01%	1360
2018 Q2	$110K	Buy	+898	New	+$76.3K	﹤0.01%	1411

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Los Angeles Capital Management's LRMR Position: Q2 2026 in Review

Los Angeles Capital Management increased its Larimar Therapeutics (LRMR) stake by 2,117% in Q2 2026, buying an estimated $1.51M and bringing the position to 399,542 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #697.

Los Angeles Capital Management first reported a position in LRMR in Q2 2018 and has held it in 6 quarters since. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Los Angeles Capital Management held 399,542 shares of Larimar Therapeutics worth $1.22M as of Q2 2026.
Los Angeles Capital Management bought 381,520 Larimar Therapeutics shares in Q2 2026, an estimated $1.51M.
Larimar Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #697 holding.
Los Angeles Capital Management first reported a position in Larimar Therapeutics in Q2 2018 and has held it in 6 quarters since.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.